HCA Healthcare Reports Strong Q4 Results, Authorizes $10 Billion Share Repurchase, and Issues Positive 2026 Guidance
Summary
HCA Healthcare reported strong fourth-quarter and full-year 2025 results, announced a significant $10 billion share repurchase program, and issued positive 2026 financial guidance.
Key Events
-
Strong Q4 and Full-Year 2025 Performance
HCA Healthcare reported a 6.7% increase in Q4 2025 revenues to $19.513 billion, with net income attributable to HCA Healthcare, Inc. rising 30.6% to $1.878 billion and diluted EPS up 44.6% to $8.14. Full-year 2025 revenues reached $75.600 billion, with diluted EPS of $28.33.
-
New $10 Billion Share Repurchase Program Authorized
The Board of Directors authorized an additional share repurchase program for up to $10 billion of the company's common stock, signaling strong confidence and a commitment to shareholder returns. This follows $10.067 billion in repurchases during 2025.
-
Positive 2026 Financial Guidance Issued
The company provided estimated guidance for 2026, projecting revenues between $76.500 billion and $80.000 billion, and diluted EPS between $29.10 and $31.50 per share, indicating continued growth.
-
Quarterly Cash Dividend Declared
HCA Healthcare declared a quarterly cash dividend of $0.78 per share, payable on March 31, 2026, to stockholders of record on March 17, 2026.
Analysis
This filing is highly significant due to the combination of robust financial performance, a substantial capital return program, and optimistic forward-looking guidance. The company reported strong fourth-quarter and full-year 2025 results, with significant increases in revenue, net income, and diluted EPS. Crucially, the Board of Directors authorized an additional $10 billion share repurchase program, representing a substantial commitment to returning capital to shareholders and signaling strong management confidence in the company's valuation and future prospects. This program follows a period where the company already repurchased over $10 billion in stock during 2025. Furthermore, the provision of positive 2026 guidance across key financial metrics reinforces a favorable outlook for the company's operational and financial trajectory.
At the time of this filing, HCA was trading at $473.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $107.8B. The 52-week trading range was $295.00 to $520.00. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.